Keywords: Astellas, Mirabegron, Overactive bladder, OAB, Regulatory approval, Ph III

Astellas to file for US/EU appro of OAB drug mirabegron on good Ph III results

Article | 23 March 2011

Print This

Japanese drug major Astellas Pharma.(TSE: 4503) today announced the results of two pivotal Phase III clinical trials for mirabegron, the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in